AVIEW LCS
Overview
Coreline Soft’s AVIEW LCS (Lung Cancer Screening) is an advanced AI-powered solution designed for the detection and analysis of lung nodules from chest CT images. The more comprehensive AVIEW LCS Plus platform offers integrated, fully automatic analysis of the “Big 3” thoracic diseases: lung cancer (pulmonary nodules), chronic obstructive pulmonary disease (COPD), and coronary artery calcification (CAC), all from a single low-dose CT scan.
Leveraging deep learning AI technology, AVIEW LCS Plus accurately detects even minute nodules, classifying them by type (solid, part-solid, non-solid) and providing detailed 3D size and volume information. It automatically quantifies emphysema (e.g., Low Attenuation Area index) and coronary artery calcification, including Agatston, volume, and mass scores, with segment-level analysis.
The system supports Lung-RADS classification and streamlines follow-up by automatically matching nodules from prior examinations to track changes in size, volume, and malignancy risk. It generates comprehensive, automated reports for patient records and insurance reimbursement, enhancing patient communication.
AVIEW LCS Plus is engineered for seamless integration into standard reading environments such as PACS and RIS. It offers flexible deployment options including cloud-based, hybrid solutions, local installation on dedicated hardware, or virtualized environments (VM, Docker). The platform can also operate as a standalone application or be embedded within third-party medical imaging platforms.
Clinical studies have shown that AVIEW LCS significantly improves lung nodule detection sensitivity, reduces false positives, and substantially decreases radiologists’ reading time. It has been adopted as a key AI solution in national lung cancer screening programs across South Korea, Germany, Italy, and other European initiatives, demonstrating its reliability and effectiveness in large-scale screening environments.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated lung nodule detection and analysis
- Lung-RADS classification and reporting
- Nodule volume quantification and 3D segmentation
- Emphysema quantification (LAA index)
- Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass)
- Automated comparison of nodules in follow-up CT scans
- Comprehensive, automated report generation
- Integration with PACS/RIS and third-party platforms
- Cloud, hybrid, local, and virtualized deployment options
- AI-powered detection and analysis from a single low-dose CT scan
Use Cases
- Lung cancer screening programs
- Early detection of lung diseases (COPD, ILD)
- Cardiovascular disease risk assessment
- Streamlining radiology workflows and reducing reading time
- Patient education and communication
- Supporting national and multi-center screening initiatives
What Physicians Need to Know
AVIEW LCS, particularly AVIEW LCS+ and AVIEW CAC, offers significant advantages for radiologists and cardiologists by automating the detection and quantification of coronary artery calcification from low-dose chest CT scans. This allows for efficient, standardized reporting and enhanced patient management through risk stratification based on established guidelines. The ability to analyze multiple diseases (lung cancer, COPD, and cardiovascular disease) from a single CT examination optimizes workflow and provides a comprehensive cardiopulmonary assessment. Physicians can leverage the detailed calcium scoring and segment-level analysis to better diagnose coronary artery disease and contribute to heart failure risk assessment. The integration capabilities further streamline the reporting process, reducing interpretation time and improving overall throughput.
AVIEW LCS is designed for flexible integration into existing clinical environments. It supports integration with standard reading environments such as PACS (Picture Archiving and Communication Systems) and RIS (Radiological Information Systems). The solution can be deployed as a stand-alone third-party application, stand-alone web-based, cloud-based, hybrid solution, or locally on dedicated hardware or virtualized environments. Coreline Soft has also demonstrated deeper integration with platforms like Incepto Medical's Tango environment, enabling the feeding of AVIEW LCS Plus measurements into a structured draft report. The output results can be extracted as CSV and PDF files, and also as Encapsulated DICOM PDF or SR (Structured Report) formats.
Details
| Category | Cardiology AI, Oncology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated AVIEW LCS received FDA 510(k) clearance in 2020. AVIEW LCS Plus, part of the AVIEW 2.0 platform, has also received FDA 510(k) clearance, meeting strengthened cybersecurity review criteria and demonstrating improved detection sensitivity and reduced false positives for lung nodules, emphysema, and coronary artery calcification from low-dose CT scans. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology |
What the Web Says
AVIEW LCS by Coreline Soft is an AI-powered solution for lung cancer screening that assists in detecting, quantifying, and characterizing pulmonary nodules from CT scans. It aims to improve diagnostic accuracy, streamline radiology workflows, and enhance early detection of lung diseases, including lung cancer, COPD, and coronary artery calcification. The software has been highlighted in several studies for its comprehensive workflow capabilities, including nodule detection, quantitative measurement, longitudinal growth assessment, and structured reporting based on Lung-RADS guidelines.
Overall: PositiveStrengths
- High accuracy in nodule detection and volume measurement, with lower likelihood of misidentifying nodules compared to human radiologists.
- Reduces radiologist workload significantly (estimated 71.2% in one study) while maintaining diagnostic safety.
- Achieved a 100% detection rate for reference positive cancers in 3-month follow-up scans.
- Supports comprehensive lung cancer screening workflows, including nodule detection, quantification, longitudinal growth assessment, and structured reporting.
- Capable of detecting lung nodules, quantifying emphysema, and analyzing coronary artery calcification from a single low-dose CT scan.
- Integrates with existing radiology infrastructure to support efficient radiologist workflows.
Limitations
- May have a slightly higher false positive rate compared to human radiologists in initial readings.
- Some advanced features and customization options may require time to learn for first-time administrators.
- A systematic review noted that AI assistance may increase false-positive results and unnecessary surveillance, and called for future research to increase specificity.
- One comparative study indicated that significant nodule volume differences between AI software tools could lead to different Lung-RADS scores in a notable percentage of cases, potentially altering participant management.
Based on reviews from: AuntMinnie, Coreline Soft, Health AI Register, The Imaging Wire, PubMed Central (PMC), Thorax
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AVIEW LCS
Videos
Product demos, reviews, and walkthroughs for AVIEW LCS.
[GER] AVIEW LCS Plus Introduction
![[GER] AVIEW Lung Texture Introduction](https://img.youtube.com/vi/ZfR-IEGqRfE/mqdefault.jpg)
Frequently Asked Questions
Compare AVIEW LCS
VS
VS
VS
VS
